Bibliographic Details
| Title: |
Artificial Intelligence and Anticancer Drug Development—Keep a Cool Head. |
| Authors: |
Bailleux, Caroline1 (AUTHOR) caroline.bailleux@nice.unicancer.fr, Gal, Jocelyn2 (AUTHOR) jocelyn.gal@nice.unicancer.fr, Chamorey, Emmanuel2 (AUTHOR) emmanuel.chamorey@nice.unicancer.fr, Mograbi, Baharia3 (AUTHOR) baharia.mograbi@unice.fr, Milano, Gérard4 (AUTHOR) gerard.milano@nice.unicancer.fr |
| Source: |
Pharmaceutics. Feb2024, Vol. 16 Issue 2, p211. 6p. |
| Subject Terms: |
*ARTIFICIAL intelligence, *DRUG development, *ANTINEOPLASTIC agents, *DRUG toxicity, *MOLECULAR structure |
| Abstract: |
Artificial intelligence (AI) is progressively spreading through the world of health, particularly in the field of oncology. AI offers new, exciting perspectives in drug development as toxicity and efficacy can be predicted from computer-designed active molecular structures. AI-based in silico clinical trials are still at their inception in oncology but their wider use is eagerly awaited as they should markedly reduce durations and costs. Health authorities cannot neglect this new paradigm in drug development and should take the requisite measures to include AI as a new pillar in conducting clinical research in oncology. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pharmaceutics is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
